Comparative Pharmacology
Head-to-head clinical analysis: DARVON COMPOUND 65 versus INVAGESIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARVON COMPOUND 65 versus INVAGESIC.
DARVON COMPOUND-65 vs INVAGESIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DARVON COMPOUND-65 contains propoxyphene, a centrally acting opioid agonist with analgesic effects primarily mediated through mu-opioid receptors. Aspirin inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. Caffeine is a CNS stimulant with additive analgesic effects.
INVAGESIC is a combination of pregabalin, an alpha2-delta ligand that inhibits presynaptic calcium channels to reduce excitatory neurotransmitter release, and meloxicam, a COX-2 selective NSAID that decreases prostaglandin synthesis via cyclooxygenase inhibition.
1 capsule (propoxyphene HCl 65 mg, aspirin 389 mg, caffeine 32.4 mg) orally every 4 hours as needed for pain; maximum 6 capsules per day.
Adults: 1-2 tablets (325 mg acetaminophen/5 mg hydrocodone) orally every 4-6 hours as needed for pain, not to exceed 12 tablets per day.
None Documented
None Documented
Propoxyphene: 6-12 hours (mean 8 h); nordextropropoxyphene: 22-30 hours (accumulates with repeated dosing; risk of toxicity)
Terminal elimination half-life: 4-6 hours in adults; prolonged to 8-12 hours in elderly or mild renal impairment
Renal: ~90% as propoxyphene and metabolites (nordextropropoxyphene); biliary/fecal: ~10%
Renal: ~70% as unchanged drug; biliary/fecal: ~30% as metabolites
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination